Plain-English translation of NCT07193680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a blood test measuring two proteins (sFlt-1 and PlGF) can help doctors decide the safest time to deliver your baby if you have high blood pressure complications of pregnancy late in your third trimester. Currently, doctors deliver babies at 37 weeks for this condition, but this trial is asking: could a blood test show us it's safe to wait longer in some cases, or that delivery needs to happen sooner in others?
High blood pressure complications in pregnancy can be serious for both mother and baby, but delivering too early can also cause problems for newborns. A blood test that predicts risk more accurately could help doctors make more personalized, safer decisions about when each person needs to deliver.
You likely qualify if…
You likely don't qualify if…
If you join, you'll have a blood test to measure the two proteins that guide your care plan. One group will have delivery scheduled at 37 weeks as usual; the other group's delivery timing will depend on their blood test results — either waiting until 39 weeks if the markers are normal, or delivering sooner if they're abnormal. You'll also answer brief questionnaires about your experience at enrollment and 4 weeks after delivery. Throughout, you'll have the same close monitoring as usual, and if any warning signs appear, your baby will be delivered immediately.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Spain